Efficient Testing Using Surrogate Information

Area of Science:

• Biostatistics
• Clinical Trial Design
• Health Economics

Background:

• Clinical trials face pressure to use surrogate markers due to cost and time constraints of primary outcomes.
• Existing methods for surrogate marker analysis often rely on strict parametric assumptions or assume universal surrogate validity.
• Heterogeneity in surrogate marker utility across patient subgroups presents a challenge for traditional analytical approaches.

Purpose of the Study:

• To develop a fully nonparametric method for efficient testing using surrogate information (ETSI).
• To address settings with heterogeneity in surrogate marker utility, where surrogates are valid only for specific patient subgroups.
• To enable robust treatment effect estimation and hypothesis testing in complex clinical trial scenarios.

Main Methods:

• Developed a fully nonparametric approach named Efficient Testing using Surrogate Information (ETSI).
• Employed kernel-based estimation for treatment effect estimation and hypothesis testing.
• Designed the method for scenarios where surrogate markers are used for valid subgroups and primary outcomes are measured in remaining patients.

Main Results:

• ETSI allows for efficient hypothesis testing and treatment effect estimation in the presence of heterogeneous surrogate marker utility.
• The method accommodates situations where the primary outcome is not measured for all participants.
• Simulation studies and application to HIV clinical trials demonstrate the method's performance.

Conclusions:

• The ETSI method provides a flexible and robust framework for utilizing surrogate markers in clinical trials with heterogeneous surrogate validity.
• This approach can lead to more timely and cost-effective decision-making regarding treatment effectiveness.
• The study offers a framework for future clinical trial design, including power and sample size estimations.